{"pmid":32478567,"title":"Can an Old Ally Defeat a New Enemy?","text":["Can an Old Ally Defeat a New Enemy?","Circulation","Gurbel, Paul A","Bliden, Kevin P","Schror, Karsten","32478567"],"journal":"Circulation","authors":["Gurbel, Paul A","Bliden, Kevin P","Schror, Karsten"],"date":"2020-06-02T11:00:00Z","year":2020,"_id":"32478567","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1161/CIRCULATIONAHA.120.047830","keywords":["covid-19","acetylsalicylic acid","cyclooxygenase-1","virus"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1668437835199283200,"score":9.490897,"similar":[{"pmid":32475006,"title":"Coronaviridae - old friends, new enemy!","text":["Coronaviridae - old friends, new enemy!","Coronaviridae is a family of single-stranded positive enveloped RNA viruses. This article aimed to review the history of these viruses in the last 60 years since their discovery to understand what lessons can be learned from the past. A review of the PubMed database was carried out, describing taxonomy, classification, virology, genetic recombination, host adaptation, and main symptoms related to each type of virus. SARS-CoV-2 is responsible for the ongoing global pandemic, SARS-CoV and MERS-CoV were responsible for causing severe respiratory illness and regional epidemics in the past while the four other strains of CoVs (229-E OC43, NL63, and HKU1) circulate worldwide and normally only cause mild upper respiratory tract infections. Given the enormous diversity of coronavirus viruses in wildlife and their continuous evolution and adaptation to humans, future outbreaks would undoubtedly occur. Restricting or banning all trade in wild animals in wet markets would be a necessary measure to reduce future zoonotic infections.","Oral Dis","Carneiro Leao, Jair","Paula de Lima Gusmao, Teresa","Machado Zarzar, Adriana","Leao Filho, Jair Carneiro","Barkokebas Santos de Faria, Andreza","Morais Silva, Igor Henrique","Gueiros, Luiz Alcino Monteiro","Robinson, Narendran Andrew","Porter, Stephen","de Albuquerque Tavares Carvalho, Alessandra","32475006"],"abstract":["Coronaviridae is a family of single-stranded positive enveloped RNA viruses. This article aimed to review the history of these viruses in the last 60 years since their discovery to understand what lessons can be learned from the past. A review of the PubMed database was carried out, describing taxonomy, classification, virology, genetic recombination, host adaptation, and main symptoms related to each type of virus. SARS-CoV-2 is responsible for the ongoing global pandemic, SARS-CoV and MERS-CoV were responsible for causing severe respiratory illness and regional epidemics in the past while the four other strains of CoVs (229-E OC43, NL63, and HKU1) circulate worldwide and normally only cause mild upper respiratory tract infections. Given the enormous diversity of coronavirus viruses in wildlife and their continuous evolution and adaptation to humans, future outbreaks would undoubtedly occur. Restricting or banning all trade in wild animals in wet markets would be a necessary measure to reduce future zoonotic infections."],"journal":"Oral Dis","authors":["Carneiro Leao, Jair","Paula de Lima Gusmao, Teresa","Machado Zarzar, Adriana","Leao Filho, Jair Carneiro","Barkokebas Santos de Faria, Andreza","Morais Silva, Igor Henrique","Gueiros, Luiz Alcino Monteiro","Robinson, Narendran Andrew","Porter, Stephen","de Albuquerque Tavares Carvalho, Alessandra"],"date":"2020-06-01T11:00:00Z","year":2020,"_id":"32475006","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1111/odi.13447","topics":["Mechanism"],"weight":1,"_version_":1668341932731924480,"score":72.17842},{"pmid":32454984,"pmcid":"PMC7237624","title":"Battling COVID-19: using old weapons for a new enemy.","text":["Battling COVID-19: using old weapons for a new enemy.","Coronavirus disease-19 (COVID-19) has reached pandemic proportions. Most of the drugs that are being tried for the treatment have not been evaluated in any randomized controlled trials. The purpose of this review was to summarize the in-vitro and in-vivo efficacy of these drugs on Severe Acute Respiratory Syndrome (SARS-CoV-2) and related viruses (SARS and Middle East Respiratory Syndrome) and evaluate their potential for re-purposing them in the management of COVID-19.","Trop Dis Travel Med Vaccines","Kumar, Rohit","Gupta, Nitin","Kodan, Parul","Mittal, Ankit","Soneja, Manish","Wig, Naveet","32454984"],"abstract":["Coronavirus disease-19 (COVID-19) has reached pandemic proportions. Most of the drugs that are being tried for the treatment have not been evaluated in any randomized controlled trials. The purpose of this review was to summarize the in-vitro and in-vivo efficacy of these drugs on Severe Acute Respiratory Syndrome (SARS-CoV-2) and related viruses (SARS and Middle East Respiratory Syndrome) and evaluate their potential for re-purposing them in the management of COVID-19."],"journal":"Trop Dis Travel Med Vaccines","authors":["Kumar, Rohit","Gupta, Nitin","Kodan, Parul","Mittal, Ankit","Soneja, Manish","Wig, Naveet"],"date":"2020-05-27T11:00:00Z","year":2020,"_id":"32454984","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1186/s40794-020-00107-1","keywords":["hydroxychloroquine","lopinavir/ritonavir","nitazoxanide","remdisivir","sars-cov-2","tocilizumab"],"topics":["Treatment"],"weight":1,"_version_":1667983494518669313,"score":63.388855},{"pmid":32470547,"pmcid":"PMC7250789","title":"Targeting Neprilysin (NEP) pathways: A potential new hope to defeat COVID-19 ghost.","text":["Targeting Neprilysin (NEP) pathways: A potential new hope to defeat COVID-19 ghost.","COVID-19 is an ongoing viral pandemic disease that is caused by SARS-CoV2, inducing severe pneumonia in humans. However, several classes of repurposed drugs have been recommended, no specific vaccines or effective therapeutic interventions for COVID-19 are developed till now. Viral dependence on ACE-2, as entry receptors, drove the researchers into RAS impact on COVID-19 pathogenesis. Several evidences have pointed at Neprilysin (NEP) as one of pulmonary RAS components. Considering the protective effect of NEP against pulmonary inflammatory reactions and fibrosis, it is suggested to direct the future efforts towards its potential role in COVID-19 pathophysiology. Thus, the review aimed to shed light on the potential beneficial effects of NEP pathways as a novel target for COVID-19 therapy by summarizing its possible molecular mechanisms. Additional experimental and clinical studies explaining more the relationships between NEP and COVID-19 will greatly benefit in designing the future treatment approaches.","Biochem Pharmacol","Mohammed El Tabaa, Manar","Mohammed El Tabaa, Maram","32470547"],"abstract":["COVID-19 is an ongoing viral pandemic disease that is caused by SARS-CoV2, inducing severe pneumonia in humans. However, several classes of repurposed drugs have been recommended, no specific vaccines or effective therapeutic interventions for COVID-19 are developed till now. Viral dependence on ACE-2, as entry receptors, drove the researchers into RAS impact on COVID-19 pathogenesis. Several evidences have pointed at Neprilysin (NEP) as one of pulmonary RAS components. Considering the protective effect of NEP against pulmonary inflammatory reactions and fibrosis, it is suggested to direct the future efforts towards its potential role in COVID-19 pathophysiology. Thus, the review aimed to shed light on the potential beneficial effects of NEP pathways as a novel target for COVID-19 therapy by summarizing its possible molecular mechanisms. Additional experimental and clinical studies explaining more the relationships between NEP and COVID-19 will greatly benefit in designing the future treatment approaches."],"journal":"Biochem Pharmacol","authors":["Mohammed El Tabaa, Manar","Mohammed El Tabaa, Maram"],"date":"2020-05-30T11:00:00Z","year":2020,"_id":"32470547","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1016/j.bcp.2020.114057","keywords":["ang (1-7)","bradykinins","coronavirus disease","endothelin-1","grp","neprilysin","fmlp"],"locations":["Neprilysin"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1668420887234215936,"score":58.51351},{"pmid":32236624,"pmcid":"PMC7169834","title":"A new threat from an old enemy: Reemergence of coronavirus (Review).","text":["A new threat from an old enemy: Reemergence of coronavirus (Review).","The new outbreak of coronavirus from December 2019 has brought attention to an old viral enemy and has raised concerns as to the ability of current protection measures and the healthcare system to handle such a threat. It has been known since the 1960s that coronaviruses can cause respiratory infections in humans; however, their epidemic potential was understood only during the past two decades. In the present review, we address current knowledge on coronaviruses from a short history to epidemiology, pathogenesis, clinical manifestation of the disease, as well as treatment and prevention strategies. Although a great amount of research and efforts have been made worldwide to prevent further outbreaks of coronavirusassociated disease, the spread and lethality of the 2019 outbreak (COVID19) is proving to be higher than previous epidemics on account of international travel density and immune naivety of the population. Only strong, joint and coordinated efforts of worldwide healthcare systems, researchers, and pharmaceutical companies and receptive national leaders will succeed in suppressing an outbreak of this scale.","Int J Mol Med","Docea, Anca Oana","Tsatsakis, Aristidis","Albulescu, Dana","Cristea, Oana","Zlatian, Ovidiu","Vinceti, Marco","Moschos, Sterghios A","Tsoukalas, Dimitris","Goumenou, Marina","Drakoulis, Nikolaos","Dumanov, Josef M","Tutelyan, Victor A","Onischenko, Gennadii G","Aschner, Michael","Spandidos, Demetrios A","Calina, Daniela","32236624"],"abstract":["The new outbreak of coronavirus from December 2019 has brought attention to an old viral enemy and has raised concerns as to the ability of current protection measures and the healthcare system to handle such a threat. It has been known since the 1960s that coronaviruses can cause respiratory infections in humans; however, their epidemic potential was understood only during the past two decades. In the present review, we address current knowledge on coronaviruses from a short history to epidemiology, pathogenesis, clinical manifestation of the disease, as well as treatment and prevention strategies. Although a great amount of research and efforts have been made worldwide to prevent further outbreaks of coronavirusassociated disease, the spread and lethality of the 2019 outbreak (COVID19) is proving to be higher than previous epidemics on account of international travel density and immune naivety of the population. Only strong, joint and coordinated efforts of worldwide healthcare systems, researchers, and pharmaceutical companies and receptive national leaders will succeed in suppressing an outbreak of this scale."],"journal":"Int J Mol Med","authors":["Docea, Anca Oana","Tsatsakis, Aristidis","Albulescu, Dana","Cristea, Oana","Zlatian, Ovidiu","Vinceti, Marco","Moschos, Sterghios A","Tsoukalas, Dimitris","Goumenou, Marina","Drakoulis, Nikolaos","Dumanov, Josef M","Tutelyan, Victor A","Onischenko, Gennadii G","Aschner, Michael","Spandidos, Demetrios A","Calina, Daniela"],"date":"2020-04-03T11:00:00Z","year":2020,"_id":"32236624","source":"PubMed","week":"202014|Mar 30 - Apr 05","doi":"10.3892/ijmm.2020.4555","topics":["Prevention"],"weight":1,"_version_":1666138490392281088,"score":54.047802},{"pmid":32320059,"title":"Potential of live pathogen vaccines for defeating the COVID-19 pandemic: history and mechanism.","text":["Potential of live pathogen vaccines for defeating the COVID-19 pandemic: history and mechanism.","The whole world has entered a terrible crisis with a huge and increasing amount of human deaths and economic loss in fighting the pandemic of COVID-19 caused by the novel coronavirus termed SARS-CoV-2. The live pathogen vaccine (LPV) strategy, which originated in ancient China for fighting smallpox, has been applied successfully in the USA military recruits for decades to control acute respiratory diseases caused by types 4 and 7 adenoviruses. This strategy has also been widely employed in veterinary medicine. These facts suggest a fast way out of the current pandemic crisis, namely that SARS-CoV-2 could be directly used as a live vaccine. Beyond the two traditional mechanisms to guarantee the LPV's safety (SARS-CoV-2 is not highly pathogenic; the LPV is inoculated bypassing the respiratory sites of pathology), three novel mechanisms to further ensure the LPV's safety are available (the virus replication is inhibited with early use of an antiviral drug; symptomatic LPV recipients are cured with convalescent plasma; the LPV is inoculated in hot seasons). This LPV strategy has multiple potential advantages over other options, and could reduce greatly the morbidity and mortality as well as economic loss caused by the pandemic. The safety and efficacy of this strategy should be investigated strictly using animal experiments and clinical trials, and even if the experiments and trials all support the strategy, it should be implemented with enough cautiousness. This article is protected by copyright. All rights reserved.","J Med Virol","Chen, Ji-Wang","Chen, Ji-Ming","32320059"],"abstract":["The whole world has entered a terrible crisis with a huge and increasing amount of human deaths and economic loss in fighting the pandemic of COVID-19 caused by the novel coronavirus termed SARS-CoV-2. The live pathogen vaccine (LPV) strategy, which originated in ancient China for fighting smallpox, has been applied successfully in the USA military recruits for decades to control acute respiratory diseases caused by types 4 and 7 adenoviruses. This strategy has also been widely employed in veterinary medicine. These facts suggest a fast way out of the current pandemic crisis, namely that SARS-CoV-2 could be directly used as a live vaccine. Beyond the two traditional mechanisms to guarantee the LPV's safety (SARS-CoV-2 is not highly pathogenic; the LPV is inoculated bypassing the respiratory sites of pathology), three novel mechanisms to further ensure the LPV's safety are available (the virus replication is inhibited with early use of an antiviral drug; symptomatic LPV recipients are cured with convalescent plasma; the LPV is inoculated in hot seasons). This LPV strategy has multiple potential advantages over other options, and could reduce greatly the morbidity and mortality as well as economic loss caused by the pandemic. The safety and efficacy of this strategy should be investigated strictly using animal experiments and clinical trials, and even if the experiments and trials all support the strategy, it should be implemented with enough cautiousness. This article is protected by copyright. All rights reserved."],"journal":"J Med Virol","authors":["Chen, Ji-Wang","Chen, Ji-Ming"],"date":"2020-04-23T11:00:00Z","year":2020,"_id":"32320059","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1002/jmv.25920","keywords":["antiviral","coronavirus","pandemic","safety","strategy","vaccine"],"locations":["China","USA"],"countries":["United States","China"],"countries_codes":["USA|United States","CHN|China"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138493636575232,"score":52.7587}]}